In recent years, sorafenib [1] and lenvatinib [2] have demonstrated efficacy in the first-line setting for advanced or metastatic differentiated thyroid cancer refractory to radioactive iodine (RAI). During the same time, the specific inhibition of BRAF in BRAF-mutated tumors showed important efficacy [3] , including in papillary thyroid cancer (PTC) [4] . Furthermore, the ability of targeted therapies to induce tumor redifferentiation and the possibility of restoring RAI uptake with kinase inhibitors in iodine-resistant PTC has been described [5, 6] . The optimal treatment strategy in BRAF-mutated PTC therefore remains to be established.
An 83-year-old man was diagnosed with a mutated BRAF V600E tall-cell variant of PTC in the left thyroid lobe, staged pT3N1bR1 after total thyroidectomy and unilateral left lymph node dissection. Tumor responses were compared after three lines of radioiodine therapy (one at diagnosis, one under vemurafenib, one in the absence of BRAF inhibition; cumulative dose, 14.7 GBq) and 10 months of BRAF inhibition (7 months of vemurafenib and 3 months of dabrafenib). The red arrow signals a pulmonary macrometastasis with 131 I restored uptake showing a partial response (60% shrinkage), the green arrow signals a pulmonary macrometastasis without 131 I restored uptake showing a partial response (67% shrinkage), and the blue arrow signals a cervical lymphadenopathy with 131 I restored uptake showing a complete response (short axis from 36 to 5 mm).
This image illustrates a multimodal therapeutic strategy for an iodine-refractory BRAF-mutated metastatic PTC. Three lessons can be highlighted. First, both BRAF inhibitors can restore RAI uptake and may help characterize or visualize lesions, such as the pulmonary miliary here. Second, the redifferentiation process appears to be limited to the period of the inhibitor pharmacologic effect, indicating that the treatment should be continued during the RAI therapy. Moreover, plasma drug monitoring should be considered to prevent erroneous conclusions. Third, imaging must be used to assess efficacy because a rise in thyroglobulin can represent disease progression, disease redifferentiation, or tumor cell lysis.
